SINUS DILATION DEVICES MARKET ANALYSIS

Global Sinus Dilation Devices Market

Sinus dilation devices play a major role in modern healthcare, allowing the sinus openings to expand during nasal sinusitis and are preferred over antibiotics, decongestants, or steroids, as it provides long-lasting and immediate results.

The global sinus dilation devices market was valued at US$ 2.7 billion in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2018 – 2026).

Figure 1. Global Sinus Dilation devices Market Value (US$ Mn), by Region, 2017

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of chronic sinusitis is expected to propel growth of the sinus dilation devices market

Sinus dilation device is used in nasal sinusitis and nose drainage issues. High prevalence of chronic sinusitis is expected to propel demand for of sinus dilation devices, which in turn is expected to drive the market growth. According to the Centers for Disease Control and Prevention (CDC), in 2016, around 26.7 million adults in the U.S. were diagnosed with chronic sinusitis. Chronic sinusitis affects 146 per 1000 people in the U.S., while in Canada the estimated prevalence of diagnosed chronic sinusitis is around 2% to 2.5% of the population. Sinusitis results in over 18-22 million physician visits per year in the U.S. The socioeconomic burden is valued at US$ 3.4-5 billion annually, for the treatment of this chronic sinusitis.

Furthermore, according to the study published in the U.S. National Library of Medicine, up to 64% of the patients suffering from acquired immune deficiency syndrome (AIDS) have possibility to develop chronic sinusitis in their course of life.

However, complications such as excessive and prolonged bleeding, post-surgical infections, which can be life threatening such as Methicillin-Resistant Staphylococcus Aureus (MRSA), and rare complications such as cerebrospinal fluid rhinorrhea are expected to limit adoption of sinus dilation devices, thereby hindering the market growth.

A study conducted by American Journal of Rhinology & Allergy in 2014, suggested that the complication rate for balloon sinuoplasty (BSP) was 5.26% and it was 7.35% for conventional functional endoscopic sinus surgery (FESS). Major complications associated with the endoscopic surgeries are due to balloon sinuplasty

Figure 2. Global Sinus Dilation Devices Market Share (%), by Design, 2018 and 2026

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2018)

Increasing adoption of sinus dilation devices in North America is expected to boost growth of the market

North America holds dominant position in the global sinus dilation devices market, owing to high availability of sinus dilation devices in medical settings. Medications such as antibiotics and topical steroids help to open up blocked sinus passages and relieve symptoms. However, these medicines serve as short-term relive and do not fix the condition permanently, therefore, many people in the U.S. are adopting surgical methods for the treatment of this condition. According to the research published in the National Center for Biotechnology Information (NCBI), over 600,000 ambulatory sinonasal cases are performed each year in the U.S.

One of the minimally invasive and most favorable technique is Balloon Sinus Dilation (BSD). The balloon sinus dilation opens inflamed sinuses restoring normal sinus drainage and function often without tissue or bone removal. According to Entellus Inc.’s annual report, around 552,000 patients underwent FESS procedures in the U.S. in 2015. Out of which, over 55% were well suited for balloon sinus dilation, and the supplementary 30% were apt for hybrid balloon sinus dilation (BSD with FESS).

Key Players

Major players operating in the global sinus dilation devices market include, Entellus Medical, Inc., Smith & Nephew Plc., Acclarent, Inc., B. Braun Melsungen AG, Medtronic Plc, Olympus Corporation, SinuSys Corporation, InnAccel Technologies, and Intersect ENT, Inc.